Navigation Links
Cancer research presented at 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium
Date:12/1/2010

SAN ANTONIO More than 9,000 people from more than 90 countries will gather Dec. 8-12, 2010, at the Henry B. Gonzales Convention Center in San Antonio, Texas, for the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.

The symposium is the largest of its kind anywhere in the world. Each year it draws academicians, clinicians, survivors, patient advocates, industry and others interested in the advancement of breast cancer research to discuss and learn about new and late-breaking research, which includes experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and pre-malignant breast disease, as well as new findings from clinical trials.

The CTRC-AACR San Antonio Breast Cancer Symposium is a partnership between the Cancer Therapy and Research Center (CTRC) at UT Health Science Center San Antonio, the American Association for Cancer Research and Baylor College of Medicine.

"The driving force behind this collaboration is the shared mission of the organizations to advance progress against breast cancer," said Program Chairperson C. Kent Osborne, M.D., director of the Dan L. Duncan Cancer Center at the Baylor College of Medicine. "By combining their respective strengths, the San Antonio Breast Cancer Symposium encompasses the full spectrum of breast cancer research and facilitates the rapid transition of new knowledge into improved care for breast cancer patients."

The symposium begins on Wednesday, Dec. 8, with a full schedule of educational events. The opening plenary session begins the next day at 8:30 a.m. CT in Exhibit Hall D of the Henry B. Gonzales Convention Center.

In addition to the ongoing plenary session, there is a full industry exhibit hall and a program for survivors and breast cancer advocates. Press conferences will be held for registered members of the media.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1

Related medicine news :

1. FDA Panel to Vote on Drugs Said to Prevent Prostate Cancer
2. Finger length points to prostate cancer risk
3. FDA Panel to Vote on Drugs to Prevent Prostate Cancer
4. Cancer risk from medical radiation may have been overestimated
5. Annual breast cancer screening beginning at age 40 reduces mastectomy risk
6. Active surveillance for low-risk prostate cancer may offer better quality-of-life
7. Breast Cancer Rates Lower With Less Hormone Therapy: Study
8. Study Backs Active Surveillance for Low-Risk Prostate Cancer
9. Celebrex may help prevent some non-melanoma skin cancers
10. Experimental vaccine sets sights on lung cancer
11. Drop in breast cancer rates directly tied to reduced hormone therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol ... is introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex ... in horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the ...
(Date:4/24/2017)... ... April 24, 2017 , ... Michael Vick announced his retirement earlier this ... The former overall number one pick in the 2001 NFL Draft, to the Atlanta ... record for the most career rushing yards by a quarterback (6,109) and the most ...
(Date:4/24/2017)... ... April 24, 2017 , ... NEPC Director Kevin Welner ... Education Research Award. The award honors scholars exemplary in their capacity to communicate ... who has demonstrated the capacity to deepen the public’s understanding and appreciation of ...
(Date:4/24/2017)... ... April 24, 2017 , ... Sean Fay is the undisputed ... Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which sold more than 100 ... in the last 25 years. , Now, due to changes in the broadcast media ...
(Date:4/24/2017)... ... April 24, 2017 , ... The world-class designers ... to bring their novel lifesaving device for the everyday use of parents worldwide. ... specially designed to read a child’s vital signs, and detect unusual symptoms or ...
Breaking Medicine News(10 mins):
(Date:4/21/2017)... 2017 Halo Labs announces the launch of ... system called the Horizon at PEGS 2017 in ... system analyzes sub visible particulate matter in biopharmaceutical samples ... as early as candidate selection and pre-formulation. ... research organization Elion Labs for system validation. ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... the "Global Biosimilar Pipeline and Market Prospects: Addressing ... report to their offering. ... "Global Biosimilar Pipeline and Market ... by Design" provides an in-depth assessment of the current ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
Breaking Medicine Technology: